查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081460

卵巢癌治療市場：2026-2032年全球市場預測（按癌症類型、療法、療法類型、給藥途徑、分銷管道和最終用戶分類）

Ovarian Cancer Drugs Market by Cancer Type, Treatment Type, Therapeutic Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，卵巢癌治療市場將成長至 119.4 億美元，複合年成長率為 14.09%。

主要市場統計數據
基準年 2025 47.4億美元
預計年份：2026年 54億美元
預測年份 2032 119.4億美元
複合年成長率 (%) 14.09%

卵巢癌治療藥物的介紹

卵巢癌的治療是腫瘤學領域最迫切的治療主題之一。這是因為卵巢癌通常在癌細胞擴散到卵巢以外後才被診斷出來。國際癌症研究機構（IARC）發布的《2022年全球癌症監測報告》（GLOBOCAN 2022）指出，全球新增卵巢癌病例超過32.4萬例，死亡人數約20.7萬，凸顯了早期診斷、持續治療以及更廣泛地應用精準腫瘤學的必要性。

卵巢癌治療的變革性變化

目前卵巢癌的治療模式正從化療為主轉向以生物標記為基礎的序貫治療模式。 PARP抑制劑核准用於特定維持治療、抗血管新生療法的確立以及抗體藥物複合體的出現，進一步提升了伴隨診斷、分子檢測、病理確診和實證治療順序的重要性。

人工智慧的累積影響

人工智慧（AI）正逐漸成為卵巢癌治療各領域的累積驅動力，從藥物發現和臨床開發到診斷和商業化。 AI驅動的標靶識別、分子建模、病理影像分析、放射組學和多體學分析能夠支持假設生成和患者分層，尤其是在腫瘤異質性和獲得性抗藥性使傳統研發路徑複雜化的情況下。

關於卵巢癌治療的關鍵區域見解

北美憑藉其先進的生物標記檢測基礎設施、高密度的腫瘤臨床試驗、標靶治療的FDA核准途徑以及對維持治療的積極應用，仍然是卵巢癌治療領域的領先地區。美國和加拿大受益於完善的婦科腫瘤網路、BRCA和同源重組缺陷檢測的廣泛應用，以及保險公司對存活率、安全性和生活品質（QOL）結果的評估。歐洲則受益於歐洲藥品管理局（EMA）的統一核准流程、國家衛生技術評估（HTA）體係以及臨床指南的廣泛一致性，儘管報銷時間和患者就醫途徑因國家而異。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，新加坡、泰國、馬來西亞、印尼、越南和菲律賓癌症中心的擴張正在影響卵巢癌治療的可及性，而PARP抑制劑、先進的病理檢測以及BRCA或同源重組缺陷檢測的普及程度仍然參差不齊。海灣合作理事會（GCC）成員國正在投資專業的癌症護理服務、國家癌症戰略、基因組醫學和醫療旅遊，以滿足阿拉伯聯合大公國、沙烏地阿拉伯、卡達、科威特、巴林和阿曼等國對創新療法的需求。

主要卵巢癌治療藥物市場的關鍵國家特定趨勢

美國在創新應用、專科藥房管道、卵巢癌臨床試驗和基於生物標記的處方方面主導，而加拿大則強調省級報銷、醫療技術評估以及公共癌症醫療體系內的公平獲取。墨西哥和巴西是拉丁美洲的關鍵國家，公共採購、私人癌症醫療網路、集中式專科護理以及診斷工具的可近性影響著治療方案的推廣。在歐洲，英國、德國、法國、義大利和西班牙將成熟的癌症醫療體系與既定的臨床指南相結合，儘管在定價、報銷和區域准入啟動方面存在差異。俄羅斯的卵巢癌治療格局受到在地化政策、採購系統、監管要求以及患者就醫機會的區域差異的影響。

為行業領導者提供的實用建議

行業領導者應將卵巢癌治療策略與生物標記定義的患者群體、循證治療方案以及支付方關注的關鍵結果相匹配。投資於BRCA基因、同源重組缺陷和葉酸受體α檢測的夥伴關係，有助於更精準地識別合格的患者，並促進大學癌症中心、區域醫院和地方癌症治療機構對這些治療方案的採納。

調查方法

本執行摘要採用結構化的研究方法編寫，優先考慮檢驗的資訊來源，包括腫瘤學指南、監管適應症、臨床試驗註冊庫、同行評審文獻、流行病學資料庫（例如 IARC GLOBOCAN）、保險報銷參考資料以及公共衛生機構出版刊物。市場分析透過交叉參考治療標準、核准歷史記錄、生物標記應用、臨床證據和區域可及性因素來進行。

結論

卵巢癌治療正朝著精準醫療的方向發展，標靶治療和生物標記檢測正在重新定義患者的選擇、治療和後續觀察方式。然而，晚期診斷率高、復發率高、含鉑類藥物抗藥性以及分子診斷可近性方面的差異，仍然為整個醫療保健系統帶來了巨大的未滿足需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章卵巢癌治療市場：依癌症類型分類

  • 上皮性卵巢癌
  • 生殖細胞腫瘤
  • 小細胞卵巢癌
  • 間質細胞瘤

第8章卵巢癌治療藥物市場：依治療類型分類

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 放射線治療
  • 標靶治療

第9章卵巢癌治療市場：依治療分類

  • 血管新生抑制劑
  • PARP抑制劑
  • PD-L1抑制劑

第10章：卵巢癌治療藥物市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章卵巢癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章卵巢癌治療藥物市場：依最終用戶分類

  • 癌症中心
  • 診所
  • 醫院

第13章卵巢癌治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章卵巢癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章卵巢癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Aravive, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • BeiGene, Ltd.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Compugen Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oncxerna Therapeutics, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Limited
  • Zentalis Pharmaceuticals, Inc.
Product Code: MRR-434CCDA052A2

The Ovarian Cancer Drugs Market is projected to grow by USD 11.94 billion at a CAGR of 14.09% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.74 billion
Estimated Year [2026] USD 5.40 billion
Forecast Year [2032] USD 11.94 billion
CAGR (%) 14.09%

Ovarian Cancer Drugs Introduction

Ovarian cancer drugs are central to one of oncology's most urgent therapeutic areas because the disease is frequently diagnosed after it has spread beyond the ovary. IARC GLOBOCAN 2022 reported more than 324,000 new ovarian cancer cases worldwide and about 207,000 deaths, underscoring the need for earlier diagnosis, durable therapies, and broader access to precision oncology.

The treatment landscape is anchored by platinum-based chemotherapy and taxanes, while targeted therapies have reshaped maintenance and recurrent-disease management. PARP inhibitors, anti-angiogenic therapy such as bevacizumab, and biomarker-directed medicines, including folate receptor alpha-targeted antibody-drug conjugates, are moving ovarian cancer drugs toward more individualized care based on BRCA status, homologous recombination deficiency, folate receptor alpha expression, prior platinum response, disease recurrence, and patient tolerability.

Transformative Shifts in Ovarian Cancer Treatment

The ovarian cancer drugs landscape is shifting from a chemotherapy-dominant model to a biomarker-led continuum of care. Regulatory approvals for PARP inhibitors in selected maintenance settings, the established role of anti-angiogenic therapy, and the emergence of antibody-drug conjugates have increased the importance of companion diagnostics, molecular testing, pathology confirmation, and evidence-based treatment sequencing.

Clinical development is also changing. Sponsors are prioritizing platinum-resistant and recurrent ovarian cancer, combination regimens, and patient subgroups with defined biomarkers. At the same time, payers and health systems are scrutinizing overall survival, progression-free survival, quality of life, treatment adherence, and toxicity management, making real-world evidence increasingly important for formulary access, clinical guideline adoption, and lifecycle strategy.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across ovarian cancer drug discovery, clinical development, diagnostics, and commercialization. AI-assisted target identification, molecular modeling, pathology image analysis, radiomics, and multi-omics interpretation can support hypothesis generation and patient stratification, particularly where tumor heterogeneity and acquired drug resistance complicate traditional development pathways.

In clinical operations, AI can improve trial feasibility, site selection, eligibility screening, adverse-event signal detection, and real-world evidence generation from electronic health records, registries, and imaging datasets. The most credible use cases remain those governed by validated datasets, transparent model performance, privacy controls, bias monitoring, clinical oversight, and regulatory-grade auditability rather than unverified automation.

Key Regional Insights Across Ovarian Cancer Drugs

North America remains a leading region for ovarian cancer drugs because of advanced biomarker testing infrastructure, high oncology trial density, FDA pathways for targeted therapies, and strong adoption of maintenance treatment. The United States and Canada benefit from established gynecologic oncology networks, increasing use of BRCA and homologous recombination deficiency testing, and payer evaluation of survival, safety, and quality-of-life outcomes. Europe benefits from centralized European Medicines Agency review, national health technology assessment systems, and broad clinical guideline alignment, although reimbursement timing and patient access vary across countries.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India strengthen oncology research, local manufacturing, regulatory review capacity, and precision diagnostics. China and Japan are particularly important for clinical trial participation and regulatory activity, while India continues to face affordability and testing-access challenges despite a substantial disease burden. Latin America shows growing demand across Brazil, Mexico, and other major health systems, but treatment availability is shaped by public procurement, private insurance, and concentration of oncology centers. The Middle East is advancing through national cancer strategies, specialty oncology investment, and tertiary-care expansion, especially in higher-income Gulf countries. Africa continues to experience uneven access to genetic testing, specialist oncology services, and targeted medicines, making affordability, diagnosis, and treatment infrastructure central to ovarian cancer drug utilization.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, ovarian cancer drug uptake is influenced by expanding cancer centers in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, while access to PARP inhibitors, advanced pathology, and BRCA or homologous recombination deficiency testing remains uneven. GCC countries are investing in specialty oncology services, national cancer strategies, genomic medicine, and medical tourism, supporting demand for innovative therapies across the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman.

The European Union provides a structured environment for centralized authorization, pharmacovigilance, clinical guideline harmonization, and health technology assessment, making evidence quality central to uptake. BRICS countries combine large patient pools with rising local clinical trial activity, expanding domestic oncology capabilities, and strong cost-containment pressure. G7 markets generally have higher diagnostic capacity, established reimbursement pathways, and deep clinical research networks, creating important launch and evidence-generation hubs. NATO countries overlap with many high-income oncology systems in North America and Europe, where treatment access is supported by advanced hospital infrastructure, regulated medicines agencies, and broader availability of molecular diagnostics, although coverage rules remain country-specific.

Key Country Insights Across Major Ovarian Cancer Drug Markets

The United States leads in innovation adoption, specialty pharmacy channels, ovarian cancer clinical trials, and biomarker-driven prescribing, while Canada emphasizes provincial reimbursement, health technology assessment, and equitable access across public oncology systems. Mexico and Brazil are important Latin American countries where public procurement, private oncology networks, centralized specialty care, and diagnostic availability shape uptake. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature oncology systems with established clinical guideline use, but pricing, reimbursement, and regional access timelines differ. Russia's ovarian cancer drug environment is shaped by localization policy, procurement systems, regulatory requirements, and variability in patient access across regions.

China is increasingly influential through domestic PARP inhibitor development, oncology trial growth, guideline evolution, and regulatory acceleration for innovative medicines. India offers a large treatment population but faces affordability barriers, uneven molecular testing access, and capacity constraints outside major urban cancer centers. Japan, South Korea, and Australia have strong clinical guideline adoption, advanced diagnostic infrastructure, and active participation in global trials, supporting precision medicine use in ovarian cancer. Australia also benefits from established public reimbursement assessment and genetic testing pathways, while South Korea's oncology ecosystem is strengthened by high hospital specialization and rapid diagnostic technology adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should align ovarian cancer drug strategies with biomarker-defined patient segments, evidence-based sequencing, and payer-relevant outcomes. Investment in BRCA, homologous recombination deficiency, and folate receptor alpha testing partnerships can improve eligible patient identification and strengthen therapy adoption across academic cancer centers, regional hospitals, and community oncology settings.

Manufacturers should build differentiated evidence packages that include overall survival, progression-free survival, quality of life, safety, treatment adherence, dose modification, and real-world outcomes. Strategic priorities include equitable access programs, diagnostic education, combination-trial design, pharmacovigilance excellence, companion diagnostic readiness, and regional pricing models that reflect differences in reimbursement capacity, testing infrastructure, and healthcare delivery.

Research Methodology

This executive summary is developed using a structured research approach that prioritizes verified sources, including oncology guidelines, regulatory labels, clinical trial registries, peer-reviewed literature, epidemiology databases such as IARC GLOBOCAN, reimbursement references, and public health authority publications. Market interpretation is triangulated across treatment standards, approval history, biomarker adoption, clinical evidence, and regional access factors.

Primary insights are strengthened through expert evaluation of oncologist practice patterns, payer considerations, diagnostic availability, treatment sequencing, and commercial readiness. The methodology avoids unsupported claims and emphasizes data-backed trends, including disease burden, therapeutic class evolution, regulatory evidence, safety considerations, and real-world implementation constraints.

Conclusion

Ovarian cancer drugs are advancing toward precision treatment, with targeted therapies and biomarker testing redefining how patients are selected, treated, and monitored. Persistent late-stage diagnosis, high recurrence rates, platinum resistance, and unequal access to molecular diagnostics continue to create significant unmet need across healthcare systems.

Future competitiveness will depend on clinically meaningful differentiation, diagnostic integration, access strategy, and credible real-world evidence. Organizations that combine strong science with patient-centered affordability, regional execution, responsible AI-enabled development, and robust safety monitoring will be best positioned to improve outcomes in ovarian cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ovarian Cancer Drugs Market, by Cancer Type

  • 7.1. Epithelial Ovarian Cancer
  • 7.2. Germ Cell Tumors
  • 7.3. Small Cell Ovarian Cancer
  • 7.4. Stromal Cell Tumors

8. Ovarian Cancer Drugs Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Hormonal Therapy
  • 8.3. Immunotherapy
  • 8.4. Radiation Therapy
  • 8.5. Targeted Therapy

9. Ovarian Cancer Drugs Market, by Therapeutic Class

  • 9.1. Angiogenesis Inhibitors
  • 9.2. PARP Inhibitors
  • 9.3. PD-L1 Inhibitors

10. Ovarian Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Ovarian Cancer Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Ovarian Cancer Drugs Market, by End User

  • 12.1. Cancer Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Ovarian Cancer Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Ovarian Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ovarian Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. Aravive, Inc.
  • 17.4. AstraZeneca PLC
  • 17.5. Aurobindo Pharma Limited
  • 17.6. Bayer AG
  • 17.7. BeiGene, Ltd.
  • 17.8. BioMarin Pharmaceutical Inc.
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Bristol-Myers Squibb Company
  • 17.11. Clovis Oncology, Inc.
  • 17.12. Compugen Ltd.
  • 17.13. Eisai Co., Ltd.
  • 17.14. Eli Lilly and Company
  • 17.15. GlaxoSmithKline plc
  • 17.16. Johnson & Johnson
  • 17.17. Merck & Co., Inc.
  • 17.18. Merck KGaA
  • 17.19. Mersana Therapeutics, Inc.
  • 17.20. Novartis AG
  • 17.21. Oncxerna Therapeutics, Inc.
  • 17.22. Pfizer Inc.
  • 17.23. Regeneron Pharmaceuticals, Inc.
  • 17.24. Roche Holding AG
  • 17.25. Sanofi SA
  • 17.26. Sun Pharmaceutical Industries Ltd.
  • 17.27. Sutro Biopharma, Inc.
  • 17.28. Takeda Pharmaceutical Company Limited
  • 17.29. Teva Pharmaceutical Industries Ltd.
  • 17.30. Zai Lab Limited
  • 17.31. Zentalis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OVARIAN CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OVARIAN CANCER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EPITHELIAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EPITHELIAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EPITHELIAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GERM CELL TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GERM CELL TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GERM CELL TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMALL CELL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMALL CELL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMALL CELL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STROMAL CELL TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STROMAL CELL TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STROMAL CELL TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HORMONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HORMONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANGIOGENESIS INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANGIOGENESIS INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANGIOGENESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARP INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARP INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARP INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. G7 OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NATO OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)